echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > More than 10 pens! In September, License-in/out was still active, involving Merck, Zaiding, Fosun, Luye Pharmaceutical, etc

    More than 10 pens! In September, License-in/out was still active, involving Merck, Zaiding, Fosun, Luye Pharmaceutical, etc

    • Last Update: 2022-10-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In September 2022, license-in and license-out transactions by local companies remained active
    .
    According to the global trading section of GBI SOURCE database, there are more than ten related transactions, most of which are License-in, mainly covering oncology, metabolism, nervous system and other fields
    .

    GBI SOURCE Global Transactions

    Table 1.
    Licensing of the introduction transaction in September 2022

    Table 1.
    Licensing of the introduction transaction in September 2022

    Source: GBI SOURCE Global Trading Sector

    GBI SOURCE

    Table 1.
    External licensing transactions in September 2022

    Table 1.
    External licensing transactions in September 2022

    Source: GBI SOURCE Global Trading Sector

    GBI SOURCE

    License the introduction of transactions

    License the introduction of transactions

    License-in

    Northeast Pharmaceutical introduced the MAb11-22.
    1 antibody project of MedAbome Company for $15 million

    Northeast Pharmaceutical introduced the MAb11-22.
    1 antibody project of MedAbome Company for $15 million

    ■ Licensor: Meida Biotechnology Co.
    , Ltd

    Licensors:

    ■Licensee: Tohoku Pharmaceutical

    Licensee:

    ■ Product/Technology: MAb11-22.
    1

    Product/Technology:

    Northeast Pharmaceutical Group Co.
    , Ltd.
    and MedAbome of the United States reached an agreement
    on the transfer, cooperative development and technical services of the MAb11-22.
    1 antibody project.
    MedAbome will transfer MAb11-22.
    1 to Northeast Pharmaceutical and provide the proprietary technology required for the project; the two companies will collaborate on the development of antibody-conjugated drugs (ADCs) and CAR-T cell therapy products
    based on this antibody.
    Northeast Pharmaceutical has MAb11-22.
    1 antibody and drugs based on the antibody in the United States, Canada, Mexico outside the three countries of the global patent rights, research and development rights, registration rights, production rights and commercialization rights
    .
    Party A has the right to transfer, and Party B cooperates; However, such transfer shall not affect Party B's rights and interests
    in this Agreement.
    At the same time, MedAbome will help and guide Northeast Pharmaceutical to design and build ADC platform and CAR-T cell therapy technology platform
    .
    Northeast Pharmaceutical paid MedAbome a down payment of US$6 million and RMB6 million, a milestone payment of US$7 million and RMB7 million after subsequent conditions, and a commission on net sales of new drugs for
    the project.

    Fosun Pharma acquired the rights and interests of Neovii anti-human T cell rabbit immunoglobulin Grafalon Greater China

    Fosun Pharma acquired the rights and interests of Neovii anti-human T cell rabbit immunoglobulin Grafalon Greater China

    ■ Licensor: Neovii Pharmaceuticals AG

    Licensors:

    ■Licensee: Fosun Pharma

    Licensee:

    ■ Product/Technology: Grafalon

    Product/Technology:

    Shanghai Fosun Pharma (Group) Co.
    , Ltd.
    recently signed an exclusive sales agent and development agreement with Neovii Pharmaceuticals AG in Switzerland to obtain Neovii's authorization to exclusively sell and develop its immunosuppressant Grafalon (anti-human T-cell rabbit immunoglobulin injection) in China,
    Hong Kong, Macao and Taiwan.
    According to the agreement, Fosun Pharma will pay Neovii a sales agent royalty and a payment based on the listing milestone of the cooperative variety, and the two parties will settle the sales
    price and sales commission.
    In addition, Fosun Pharma may authorize its subsidiaries to commercialize
    the cooperative varieties.

    Star Cerrijin acquired the exclusive rights of corneal regeneration therapy from Cellusion Corporation of Japan

    Star Cerrijin acquired the exclusive rights of corneal regeneration therapy from Cellusion Corporation of Japan

    ■ Licensor: Cellusion Inc.

    Licensors:

    ■ Licensee: Star Sai Ruizhen

    Licensee:

    ■ Product/Technology: CLS001

    Product/Technology:

    Hangzhou Xingsai Ruizhen Biotechnology Co.
    , Ltd.
    , a subsidiary of Fosun Pharma, entered into a licensing agreement with Cellusion
    , a Japanese regenerative medicine company.
    Under the agreement, Starcer will receive the rights
    to develop, manufacture and commercialize CLS001, Cellusion's leading regenerative therapy candidate.
    CLS001 is a corneal endothelial cell replacement derived from induced pluripotent stem cells (IPSCs), providing a new option
    for human corneal transplantation alternatives.
    Star Celeste will be granted the exclusive right
    to develop CLS001 in Chinese mainland, Hong Kong, Macau and Taiwan for the treatment of large vesicular corneal lesions, the main cause of blindness requiring corneal transplantation.
    Cellusion will receive payments in excess of $100 million, including upfront and milestone payments, as well as royalties
    based on future sales.

    Chemchemie has obtained an exclusive license for Voronoi's pan-RAF inhibitors

    Chemchemie has obtained an exclusive license for Voronoi's pan-RAF inhibitors

    ■ Licensor: Voronoi

    Licensors:

    ■Licensee: Yaktai Pharmaceutical

    Licensee:

    ■ Product/Technology: Type II pan-RAF kinase inhibitor

    Product/Technology:

    Pharma Pharma announces an agreement
    with Voronoi, Inc.
    of South Korea.
    Pharma will receive exclusive permission
    to develop and commercialize Voronoi's pan-RAF inhibitor project worldwide.
    Voronoi will receive up to $1.
    7 million in cash for down payments, up to $480.
    5 million in development, regulatory and sales milestone payments, and tiered royalties
    based on annual net sales.
    Otek Pharma will acquire exclusive rights to a type II pan-RAF kinase inhibitor developed by Voronoi, which is designed to target class II and III BRAF mutations
    that the current generation of RAF inhibitors have not addressed.

    Over $300 million! Chia Tai Tianqing introduces NASH medicine Lanilano Greater China interest

    Over $300 million! Chia Tai Tianqing introduces NASH medicine Lanilano Greater China interest

    ■ Licensor: Inventiva Pharma

    Licensors:

    ■ Licensee: Chia Tai Tianqing

    Licensee:

    ■ Product/Technology: Lanilano

    Product/Technology:

    Chia Tai Tianqing, a Chinese biopharmaceutical subsidiary, has entered into a license agreement with French biotechnology company Inventiva S.
    A.
    to develop, manufacture and commercialize LaniLanifibranor
    in Chinese mainland, Hong Kong, Macau, Taiwan (Greater China).
    The product is Inventiva's core product for the treatment of non-alcoholic steatohepatitis and other potential metabolic disorders
    .
    Chia Tai Tianqing will pay Inventiva a $12 million down payment, $5 million in potential milestone payments, and $290 million in clinical, registration, and commercialization milestone payments (China Biopharma Announcement reports a $12 million down payment + $40 million in potential clinical and registration milestone payments
    ).
    。 After the product is approved for marketing in Greater China, Chia Tai Tianqing will pay additional commercialization milestone payments and tiered commissions based on net sales in Greater China, and Inventiva will receive high single-digit to medium-double-digit royalties and low to mid-double-digit royalties
    starting in the 4th year.

    Hansen Pharmaceuticals received €66 million in KiOmed Osteoarthritis Drugs Chinese mainland, Macau and Taiwan

    Hansen Pharmaceuticals received €66 million in KiOmed Osteoarthritis Drugs Chinese mainland, Macau and Taiwan

    ■ Licensor: KiOmed Pharma

    Licensors:

    ■Licensee: Hansen Pharmaceuticals

    Licensee:

    ■ Product/Technology: KiOmedine One

    Product/Technology:

    Hansen Pharmaceutical Group Co.
    , Ltd.
    announced that its wholly-owned subsidiaries, Hansen (Shanghai) Health Technology Co.
    , Ltd.
    , Jiangsu Haosen Pharmaceutical Group Co.
    , Ltd.
    and Jiangsu Hengte Pharmaceutical Sales Co.
    , Ltd.
    , have reached an agreement
    with KiOmed Pharma SA.
    Hansen Pharma obtained an exclusive license from KiOmed to develop and commercialize KiOmedine One for the treatment
    of osteoarthritis in Chinese mainland, Macau and Taiwan.
    Hansen Pharma will be responsible for the development, registration approval and commercialization of KiOmedine One and its future osteoarthritis expansion indications in the authorized area, and will pay advance payments and potential payments for development, registration and commercialization milestones based on sales totaling no more than €66 million, as well as double-digit graded royalties
    based on future net sales of the product.

    Zaiding Pharma acquired the exclusive rights and interests of Seagen cervical cancer ADC drug TIVDAK in Greater China

    Zaiding Pharma acquired the exclusive rights and interests of Seagen cervical cancer ADC drug TIVDAK in Greater China

    ■ Licensor: Seagen INC.

    Licensors:

    ■Licensee: Zai Ding Pharmaceutical

    Licensee:

    ■ Product/Technology: TIVDAK

    Product/Technology:

    Zai Ting Pharma announced an exclusive partnership and licensing agreement
    with Seagen Inc.
    , a U.
    S.
    -based biotechnology company, for the development and commercialization of an antibody-conjugated drug (ADC) TIVDAK (tisotumab vedotin-tftv) in Chinese mainland, Hong Kong, Macau and Taiwan.
    TIVDAK is the first and currently the only ADC
    approved in the United States for the treatment of adults with recurrent or metastatic cervical cancer who develop disease progression during or after chemotherapy.
    Under the terms of the agreement, Seagen will receive an advance payment of $30 million, plus development, registration and commercialization milestone payments, as well as TIVDAK's net sales tiered royalties
    in Zai Ding Pharma's licensed area.

    Merck granted Sinopharm Monoravir the right to distribute and import exclusively in China

    Merck granted Sinopharm Monoravir the right to distribute and import exclusively in China

    ■ Licensor: Merck

    Licensors:

    ■Licensee: Sinopharm Group

    Licensee:

    ■ Product/Technology: Monupiravir

    Product/Technology:

    Merck announced the signing of a cooperation framework agreement
    with Sinopharm.
    Merck granted Sinopharm the distribution and exclusive import rights to molnupiravir, an oral anti-coronavirus drug developed in collaboration with Ridgeback, and the two sides will assess the feasibility of technology transfer for the production, supply and commercialization
    of the drug in China.
    Monoravir is an oral small molecule new crown virus treatment drug
    .
    Worldwide, Monoravir has obtained marketing or emergency use authorizations
    in more than 40 countries or regions, including the United States, the European Union, Australia, Japan, South Korea, Hong Kong and Taiwan.

    External licensing transactions

    External licensing transactions

    License-out

    Merck is awarded a global license for Nerviano Medical Sciences PARP1 inhibitors

    Merck is awarded a global license for Nerviano Medical Sciences PARP1 inhibitors

    ■ Licensor: Nerviano Medical Sciences S.
    r.
    l

    Licensors:

    ■ Licensee: Merck

    Licensee:

    ■ Product/Technology: NMS-293

    Product/Technology:

    Nerviano Medical Sciences, an Italian company invested by Haichen Pharmaceuticals, recently announced that it has entered into a cooperation and licensing agreement
    with Merck Healthcare, a subsidiary of Merck Healthcare, Germany.
    Under the agreement, Merck will be granted the rights
    to develop and commercialize the polymerization (ADP-ribose) polymerase 1 (PARP1) inhibitor NMS-293 worldwide.
    Merck will pay a $65 million upfront payment, as well as milestone payments and royalties
    based on future sales.
    In November 2017, Huaxi Shares, Haichen Pharmaceutical, Gaoyan Venture Capital, Eucalyptus Capital, etc.
    announced that they jointly invested in the acquisition of 90% of the equity of Nerviano Medical Sciences, and in March 2018, the transaction was completed
    .

    Meitheal and HKF received US$6 million USD in Albumin Paclitaxel from Shuangcheng Pharmaceuticals

    Meitheal and HKF received US$6 million USD in Albumin Paclitaxel from Shuangcheng Pharmaceuticals

    ■ Licensor: Shuangcheng Pharmaceutical

    Licensors:

    ■ Licensees: Meitheal Pharmaceuticals, Hong Kong King-Friend Industrial Co.
    , Ltd.

    Licensee:

    ■ Product/Technology: Paclitaxel, albumin

    Product/Technology:

    Hainan Shuangcheng Pharmaceutical Co.
    , Ltd.
    announced the signing of licensing and supply agreements
    with Meitheal Pharmaceuticals, Inc.
    and Hong Kong King-Friend Industrial Co.
    , Ltd.
    Shuangcheng Pharmaceuticals granted Meitheal and HKF
    an exclusive licensing interest in its injectable paclitaxel (albumin-conjugated, 100mg/bottle) in the United States.
    Meitheal is responsible for the marketing planning and sales of injectable paclitaxel (albumin-conjugated) in the United States, and after the product is listed, Meitheal shall pay Shuangcheng Pharmaceutical for the profit share
    generated by the sale of the product in the United States.
    HKF is required to pay a certain one-time milestone payment to Shuangcheng Pharmaceutical, totaling US$6 million
    .

    Luye Pharmaceutical and ICI Pakistan have reached a distribution and promotion cooperation license in Pakistan

    Luye Pharmaceutical and ICI Pakistan have reached a distribution and promotion cooperation license in Pakistan

    ■ Licensor: Green Leaf Pharmaceutical

    Licensors:

    ■ Licensee: ICI Pakistan

    Licensee:

    ■ Product/Technology: SilkConnect

    Product/Technology:

    According to reports, Luye Pharmaceutical Group has reached a cooperation with Pakistani company ICI Pakistan to grant its subsidiary Serikang (quetiapine fumarate, immediate-release) exclusive distribution and promotion rights
    in the Pakistani market.
    Stricon is used for the treatment of schizophrenia and bipolar disorder and is recommended by authoritative guidelines in many countries
    .

    *Log in to the global trading section of GBI SOURCE database to learn more

    GBI SOURCE Global Transactions

    Over $500 million! Simcere Pharma granted Almirall an interest in the autoimmune drug candidate SIM0278 outside Greater China

    Over $500 million! Simcere Pharma granted Almirall an interest in the autoimmune drug candidate SIM0278 outside Greater China

    ■ Licensor: Simcere Pharmaceuticals

    Licensors:

    ■Licensee: Almirall S.
    A.

    Licensee:

    ■ Product/Technology: SIM0278

    Product/Technology:

    Simcere Pharmaceuticals announces an exclusive licensing agreement
    with Almirall S.
    A.
    Under the agreement, Almirall will acquire the exclusive rights
    to develop and commercialize all indications outside Greater China for Simcere Pharmaceuticals' autoimmune drug candidate SIM0278.
    Simcere Pharmaceuticals will receive a down payment of $15 million from Almirall and up to $492 million in development and commercial milestone payments based on possible outcomes for multiple indications, including partial sales milestones, and a low double-digit percentage tiered commission
    based on future sales of the product in the agreed territories.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.